|1.||Ríos, Camilo: 7 articles (06/2015 - 03/2004)|
|2.||Matsuoka, Masanori: 6 articles (11/2013 - 09/2003)|
|3.||Diaz-Ruiz, Araceli: 5 articles (06/2015 - 11/2008)|
|4.||Zillikens, D: 5 articles (08/2012 - 02/2000)|
|5.||Zillikens, Detlef: 5 articles (10/2011 - 05/2002)|
|6.||Garrett, Steven: 5 articles (01/2010 - 01/2007)|
|7.||Nava-Ruiz, Concepción: 4 articles (06/2015 - 03/2004)|
|8.||Shen, Jianping: 4 articles (03/2015 - 01/2011)|
|9.||Ishii, Norihisa: 4 articles (12/2013 - 09/2005)|
|10.||Kai, Masanori: 4 articles (12/2013 - 09/2004)|
12/01/2012 - "The response to dapsone 5% gel appears to be influenced by gender, with female patients experiencing a significantly greater reduction in acne lesion counts and a significantly higher clinical success rate following 12 weeks of treatment. "
10/01/2007 - "These results show that dapsone gel 5% is safe and effective for long-term treatment of acne vulgaris and has a rapid onset of action."
03/01/2007 - "Dapsone gel, 5% appears to be an effective, safe, and well-tolerated treatment for acne vulgaris, with a rapid onset of action."
01/01/2015 - "Overall, these data suggest that efficacy of dapsone 5% gel twice daily for facial acne vulgaris may be greater in the adult female population."
01/01/2014 - "Topical dapsone 5% gel for the treatment of mild to moderate acne has been shown to be effective in randomized controlled studies. "
|2.||Leprosy (Hansen's Disease)
09/01/1999 - "6) In cases cured with dapsone therapy, there was an increase or a persistence of high OD values in ND-ELISA prior to the onset of a leprosy relapse. "
06/01/2009 - "The study aimed to analyse the effect on the relapse rate of dapsone-cured multibacillary (MB) leprosy patients, of re-treatment, using a multidrug therapy (MDT) regimen which differed from the WHO recommended regimen. "
06/01/2009 - "leprae threatened leprosy control programmes, and increased the relapse rate of patients cured with dapsone monotherapy. "
03/01/2002 - "Serial antibody levels were measured in 666 leprosy patients after being cured with dapsone monotherapy. "
12/01/1999 - "Based upon the data from the Chinese National System for Leprosy Surveillance, this paper reports on the relapses in 297,343 leprosy patients [multibacillary (MB) 106,518, paucibacillary (PB) 190,825] cured by dapsone monotherapy. "
08/01/1993 - "Dapsone is well-tolerated in children and appears to be as effective in preventing PCP in children with human immunodeficiency virus infection as it is in adults."
04/01/1989 - "However, treatment with dapsone (DDS) in the last 12 weeks of infection resulted in an initial enhancement of the humoral responses followed by a gradual decrease, though they were still significantly high at the end of the study."
09/01/1985 - "Studies were undertaken in three independent centers to compare the newer, in vitro radiometric macrophage (M phi) assay with the conventional mouse foot pad infection for the diagnosis of dapsone resistance. "
09/01/1952 - "[Action of diaminodiphenylsulfone on Nocardia brasiliensis; studies in vitro, in experimental infection and in the clinic]."
10/24/2013 - "Dapsone is used in the treatment of infections and inflammatory diseases. "
|4.||Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
05/01/1999 - "Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. "
01/01/2000 - "Were considered as eligible: randomized clinical trials, conducted in adults, with one arm evaluating dapsone as prophylactic agent for Pneumocystis Carinii Pneumonia (PCP). "
01/01/1991 - "We conclude that high-dose, single-agent dapsone is not suitable for further study as therapy for Pneumocystis carinii pneumonia."
01/01/1991 - "In a prospective, noncomparative study, seven patients with mild Pneumocystis carinii pneumonia, characterized by room air arterial PO2 greater than 60 mm Hg at the time of presentation, were treated with dapsone alone at a dose of 200 mg daily. "
02/01/2014 - "After an outbreak of Pneumocystis pneumonia (PCP) in our nephrology unit, dapsone was used as the second-line chemoprophylactic agent. "
11/01/1997 - "Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report."
09/01/1990 - "We describe the clinical, serologic and immunogenetic data in a patient with manifestations of Sjögren's syndrome who developed urticarial vasculitis and photosensitive annular SCLE which were effectively treated with oral dapsone. "
11/01/2011 - "[Dapsone for chronic skin lesions in 3 children suffering from Henoch-Schönlein vasculitis]."
08/01/2010 - "We report a case of hypocomplementemic urticarial vasculitis (MacDuffie syndrome) treated with dapsone with a favorable outcome. "
08/01/2010 - "[Hypocomplementemic vasculitis treated with dapsone]."
|4.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
|7.||Immunoglobulin A (IgA)
|9.||Adrenal Cortex Hormones (Corticosteroids)
|2.||Renal Dialysis (Hemodialysis)
|3.||Drug Therapy (Chemotherapy)